Clinical Trial Update: European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

View source ↗

Summary

European observational study evaluating enzalutamide in metastatic castration-resistant prostate cancer has completed. The study's findings are expected to prov…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)

Snippet

Sponsor: Astellas Pharma Europe Ltd. | Conditions: Metastatic Castration Resistant Prostate Cancer | Status: COMPLETED